SETD2 detection may reveal response to induction therapy and survival profile in acute myeloid leukemia patients.

OBJECTIVE

SET domain containing protein 2 (SETD2) involves in the progression and development of chemotherapy resistance in acute myeloid leukemia (AML). Hence, this study aimed to investigate the relationship of SETD2 expression with disease risk, features, treatment response, and survival profile in AML.

METHODS

One-hundred and sixty primary AML patients were retrospectively analyzed. Their bone marrow (BM) samples before and after induction therapy were retrieved for SETD2 detection by RT-qPCR. Moreover, SETD2 expression in BM samples of 20 disease controls (DCs) were also determined.

RESULTS

SETD2 expression was downregulated in AML patients compared to DCs (< 0.001). Higher SETD2 expression related to white blood cells ≤10 × 10/L despite not reaching statistical significance (= 0.062). One-hundred and nineteen (74.4%) AML patients achieved complete response (CR), while the remaining 41 (25.6%) did not achieve that. Furthermore, increased SETD2 expression was associated with CR achievement (= 0.015). Survival analyses displayed that SETD2 high (vs. low) was related to prolonged event-free survival (EFS) (= 0.001) and overall survival (OS) (= 0.021). Moreover, increased SETD2 quartile was correlated with favorable EFS (= 0.004) and OS (= 0.042). After adjustment using multivariate Cox's regression analysis, higher SETD2 quartile was independently related to prolonged EFS [hazard ratio (HR): 0.766, = 0.013] and OS (HR: 0.669, = 0.013). It was also noticed that SETD2 expression was elevated during the induction therapy (< 0.001).

CONCLUSION

Detection of SETD2 may assist in estimating treatment response and survival profile in AML patients.